NCT05065372View on ClinicalTrials.gov

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

March 1, 2027

Study Completion Date

July 31, 2027

Conditions
Type 1 DiabetesDiabetic Kidney DiseaseCardiovascular DiseasesEndothelial DysfunctionInsulin Sensitivity
Interventions
DRUG

Metformin Hcl 1000Mg Tab

Agent used to modify insulin sensitivity

DRUG

Aminohippurate Sodium 20 % Injection

Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance

DRUG

Iohexol 300 Mg/mL Injectable Solution

Diagnostic aid/agent used to measure glomerular filtration rate

DRUG

Placebo

Identical to Metformin Hcl 1000Mg Tab but without metabolic effects

Trial Locations (2)

80045

ACTIVE_NOT_RECRUITING

Children's Hospital Colorado/University of Colorado Anschutz Medical Campus, Aurora

98102

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

University of Colorado, Denver

OTHER

lead

Kalie Tommerdahl

OTHER